Treatment-resistant depression is one of the most challenging conditions in psychiatry. Patients who have tried multiple antidepressants, adjustments in therapy, and other conventional approaches without finding adequate relief often feel they’ve exhausted their options. The emergence of Spravato and ketamine-assisted therapy has changed that picture significantly, offering two distinct pathways to meaningful improvement for patients who had previously run out of roads to try.
This article covers both treatments, how they work, who they’re suited for, and what the practical experience of each involves. Whether you’ve been directed here by a provider or are researching independently, understanding these options clearly will help you engage more productively with the specialists who can help you move forward. For patients in New York City, Village TMS offers both treatments as part of a comprehensive interventional psychiatry program.
Understanding Spravato: The FDA-Approved Option
Spravato is the brand name for esketamine, a nasal spray form of a ketamine-derived compound that received FDA approval in 2019. It was the first genuinely new class of antidepressant medication approved in decades, and its approval was significant both clinically and symbolically, representing formal regulatory recognition of ketamine’s psychiatric potential.
Spravato works on the glutamate system through NMDA receptor antagonism, the same general mechanism as IV ketamine, but its specific molecular structure means it can be delivered effectively via nasal spray rather than requiring intravenous administration. It’s approved for use alongside an oral antidepressant rather than as a standalone treatment.
According to the FDA’s prescribing information for Spravato, the treatment must be administered in a certified healthcare setting under direct supervision, with patients remaining at the clinic for at least two hours after each dose for monitoring. This requirement reflects both the potential for dissociative side effects and the importance of clinical oversight in optimizing the treatment experience.
Who Is Spravato Approved For?
Spravato has two FDA-approved indications:
- Treatment-resistant depression (TRD): major depressive disorder that has not responded adequately to at least two different antidepressant medications
- Major depressive disorder with acute suicidal ideation or behavior (MDD-SI): for patients experiencing active suicidal thoughts as part of a current depressive episode
For both indications, Spravato is used alongside an oral antidepressant. The combination approach has been shown in clinical trials to produce significantly faster and more substantial improvements in depressive symptoms than antidepressant medication alone.
Insurance coverage is one of Spravato’s most significant practical advantages. Because it’s FDA-approved, it’s covered by most major commercial insurance plans for patients who meet the clinical criteria. The prior authorization process requires documentation of prior treatment failures, but a quality clinic will manage this on your behalf.
The Spravato Treatment Schedule
A standard Spravato treatment course follows a structured schedule:
- Induction phase: two sessions per week for four weeks
- Maintenance phase one: one session per week for four weeks
- Maintenance phase two: one session every one to two weeks, individualized based on response
Each session involves self-administering the nasal spray under clinical supervision, followed by a mandatory two-hour observation period. During this window, patients may experience dissociative effects, dizziness, or nausea, which are monitored by the clinical team and resolve before patients leave.
The total time commitment per session, including the observation period, is approximately two and a half to three hours. Most patients find the experience manageable once they know what to expect, and the dissociative effects typically become less pronounced as treatment progresses.
Ketamine-Assisted Therapy: A Different Kind of Treatment
Where Spravato is a pharmacological treatment with a defined regulatory framework, ketamine-assisted therapy (KAT) is a more integrative approach that combines the neurological effects of ketamine with structured psychotherapy. The two treatments share a common biochemical foundation but differ significantly in their structure, goals, and patient experience.
In KAT, a therapist works with the patient before, during, and after ketamine sessions. Preparation sessions help establish therapeutic context and intentions. During the infusion, the therapist is present to provide support and gentle guidance. Integration sessions following each infusion help the patient process the experience, make meaning of any insights or emotions that arose, and connect them to broader therapeutic goals.
The rationale for this approach is that ketamine’s neuroplasticity effects create a period during which the brain is particularly receptive to forming new patterns. With therapeutic support, patients can use this window to engage more productively with material that may be difficult to access through conventional therapy alone.
Which Patients Tend to Benefit Most from KAT?
Ketamine-assisted therapy tends to produce the strongest results for patients whose conditions have significant psychological complexity at their root. This includes:
- Treatment-resistant depression with underlying trauma or significant adverse life experiences
- PTSD, particularly complex or chronic presentations where conventional trauma therapy has had limited impact
- Anxiety disorders characterized by deeply ingrained avoidance patterns or cognitive distortions
- Patients who have benefited from therapy in the past but feel they’ve reached a plateau
- Patients open to an experiential, exploratory treatment process
Choosing Between Spravato and Ketamine-Assisted Therapy
For patients considering both options, a few key factors typically drive the decision:
Insurance coverage strongly favors Spravato. If cost is a significant consideration and you meet the clinical criteria for treatment-resistant depression, Spravato is the more financially accessible option. IV ketamine, including in KAT protocols, is generally not covered by insurance.
Clinical profile drives the choice between pharmacological and integrated approaches. If your depression has strong biological roots and you’re primarily seeking symptom relief, Spravato may be the cleaner starting point. If psychological complexity, trauma, or entrenched patterns are central to your experience, the added therapeutic layer of KAT may produce more durable outcomes.
Both options require a thorough psychiatric evaluation to confirm appropriateness. A qualified provider will help you understand which is the better fit for your specific situation rather than defaulting to whichever they happen to offer.
Finding the Right Provider in New York City
Both Spravato and ketamine-assisted therapy require providers with specific expertise and appropriate facilities. For Spravato, confirm that the clinic is enrolled in the Spravato REMS program, which sets standards for patient monitoring and facility requirements. For KAT, look for a treatment team that includes both a qualified psychiatrist and a therapist with specific training in ketamine-assisted modalities.
Patients searching for Spravato near me in New York City will find that Village TMS offers both Spravato administration and ketamine-assisted therapy through a psychiatry-led program. Their team provides thorough evaluations, full insurance support for Spravato, and individualized treatment planning across both modalities.
Final Thoughts
Spravato and ketamine-assisted therapy represent two of the most significant advances in depression treatment available today. They work on fundamentally different principles than conventional antidepressants, produce effects on a different timeline, and suit different patient profiles.
For patients who have tried conventional approaches without finding adequate relief, understanding these options clearly and engaging with a qualified provider who can guide you toward the right choice is a genuinely important step. Relief is more accessible than it may feel at this point in your treatment journey.
